Essex Bio-Technology (HK:1061) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Essex Bio-Technology Limited has announced that its subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has gained approval from China’s National Medical Products Administration to commercialize a new preservative-free unit-dose Diquafosol Sodium Eye Drop for treating dry eye syndromes. This product adds to the company’s existing portfolio of preservative-free eye treatments, indicating a potential expansion in the PRC’s healthcare market.
For further insights into HK:1061 stock, check out TipRanks’ Stock Analysis page.